ERBB2 and breast cancer: A higher TIL score and a higher level of programmed cell death-ligand 1 (PD-L1) expression were found to be significantly correlated with a higher pathological complete response (pCR) rate and better outcome of neoadjuvant immunotherapy for BC with a TN or a HER2 ( +) subtype [10, 11].